Yabao Links With Lawson For Innovative Sepsis Drug
This article was originally published in PharmAsia News
Executive Summary
With the aim of providing new cures for a global unmet medical need in sepsis, China’s Yabao Pharmaceutical and its strategic partner Lawson have completed discovery validation work for annexin A5-based products under a newly announced license agreement. An IND filing is expected in 2016.